| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| 10g | |||
| 50g | |||
| Other Sizes |
Purity: ≥98%
| Targets |
Serotonin Transporter (SERT, human) (Ki = 1.6 ± 0.2 μM) [1]
|
|---|---|
| ln Vitro |
Gongronema latifolium and Cinchona contain the cinchoni alkaloid cinchonidine (α-Quinidine). Building blocks for organic chemistry's asymmetric synthesis. Serotonin transporter (SERT) weak inhibitors: 330, 4.2, 36, 196, and 15 μM for dSERT, hSERT, hSERT I172M, hSERT S438T, and hSERT Y95F, respectively [1].
Cinchonidine exhibited stereoselective inhibitory activity against the human serotonin transporter (SERT). It competitively inhibited the uptake of [³H]-serotonin into HEK293 cells stably expressing human SERT, with a Ki value of 1.6 ± 0.2 μM. This affinity was significantly higher than that of its enantiomer, cinchonine (Ki = 3.8 ± 0.5 μM). The inhibition was concentration-dependent, with no significant cross-reactivity against dopamine transporters (DAT) or norepinephrine transporters (NET) at concentrations up to 10 μM [1] |
| Enzyme Assay |
Radioligand binding assay: Membrane preparations from HEK293 cells expressing human SERT were incubated with [³H]-paroxetine (a selective SERT ligand) and increasing concentrations of Cinchonidine at 25°C for 60 minutes. Non-specific binding was determined in the presence of excess unlabeled paroxetine. Bound radioactivity was separated by vacuum filtration and quantified using a scintillation counter, and Ki values were calculated via nonlinear regression analysis of competition binding curves [1]
- Serotonin uptake assay: HEK293-SERT cells were seeded in 24-well plates and preincubated with Cinchonidine for 15 minutes at 37°C in a CO₂ incubator. [³H]-serotonin was then added to each well at a final concentration of 50 nM, and the incubation continued for 10 minutes. The uptake reaction was terminated by washing the cells twice with ice-cold buffer. Cells were lysed, and intracellular radioactivity was measured by scintillation counting to assess the inhibitory effect of Cinchonidine on SERT-mediated serotonin transport [1] |
| References | |
| Additional Infomation |
Cinchonidine is 8-epico-cinconan, in which the hydrogen at position 9 is replaced by a hydroxyl group (R configuration). It is a diastereomer of cinconan, found in the bark of most cinchona shrubs, and is often used for chiral guidance in asymmetric synthesis. It is a metabolite. It is a cinchona alkaloid and also a (8xi)-cinconan-9-ol. It is derived from the hydride of (8S)-cinconan.
Cinconidine has been reported to be found in cinchona trees, cinchona plants, and other organisms with relevant data. Cinconidine is a natural quinoline alkaloid isolated from cinchona bark with well-defined antimalarial activity. In this study, it was identified as a stereoselective inhibitor of SERT, a key target for regulating serotonergic neurotransmission. The competitive binding mode of this drug to SERT suggests that, in addition to its known antimalarial use, it may be used to treat neurological disorders involving serotonin dysregulation [1]. |
| Molecular Formula |
C19H22N2O
|
|
|---|---|---|
| Molecular Weight |
294.39
|
|
| Exact Mass |
294.173
|
|
| CAS # |
485-71-2
|
|
| Related CAS # |
485-71-2;524-54-9 (2HCl);524-57-2 (HCl);524-61-8 (sulfate);
|
|
| PubChem CID |
101744
|
|
| Appearance |
White to off-white solid powder
|
|
| Density |
1.2±0.1 g/cm3
|
|
| Boiling Point |
464.5±30.0 °C at 760 mmHg
|
|
| Melting Point |
204-206ºC
|
|
| Flash Point |
234.7±24.6 °C
|
|
| Vapour Pressure |
0.0±1.2 mmHg at 25°C
|
|
| Index of Refraction |
1.652
|
|
| LogP |
3.35
|
|
| Hydrogen Bond Donor Count |
1
|
|
| Hydrogen Bond Acceptor Count |
3
|
|
| Rotatable Bond Count |
3
|
|
| Heavy Atom Count |
22
|
|
| Complexity |
412
|
|
| Defined Atom Stereocenter Count |
4
|
|
| SMILES |
C=C[C@H]1CN2CC[C@H]1C[C@H]2[C@@H](C3=CC=NC4=CC=CC=C34)O
|
|
| InChi Key |
KMPWYEUPVWOPIM-KODHJQJWSA-N
|
|
| InChi Code |
InChI=1S/C19H22N2O/c1-2-13-12-21-10-8-14(13)11-18(21)19(22)16-7-9-20-17-6-4-3-5-15(16)17/h2-7,9,13-14,18-19,22H,1,8,10-12H2/t13-,14-,18-,19+/m0/s1
|
|
| Chemical Name |
(R)-quinolin-4-yl((1S,2S,4S,5R)-5-vinylquinuclidin-2-yl)methanol
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.49 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.49 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.49 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3969 mL | 16.9843 mL | 33.9685 mL | |
| 5 mM | 0.6794 mL | 3.3969 mL | 6.7937 mL | |
| 10 mM | 0.3397 mL | 1.6984 mL | 3.3969 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA